We produce MPN Life newsletter which includes the latest in research, patient tips, health care and fundraising updates as well as other items of interest to the MPN community.
Want to keep up to date? Download our MPN Life newsletters.
If you would like to be featured in our patient stories contact info@mpnvoice.org.uk.
The newsletter for people with MPNs
MPNs in Young Patients, celebrating 10 years of buddies and much more
Closing the gap: the genetic landscape of MPNs since the discovery of the JAK2 mutation.
Research shows that the order of mutation acquisition drives different disease sub-types.
During October I attended the European School of Haematology MPN meeting in Estoril, Portugal. This meeting is essentially ‘a workshop with an audience’…
Anew blood test can now be used to diagnose the vast majority of patients with myeloproliferative neoplasms (MPNs).
The world for patients with MPNs changed significantly with the description of the JAK2 V617F mutation, dramatically improving the accuracy and speed…
INthe November 2012 issue of MPDlife readers were updated on the results of the US studies that led to the approval of Ruxolitinib as a new and effective…
Professor Verstovsek’s interest and involvement in looking for new drugs and therapies for myeloproliferative disorder (MPD) patients started as far back…
There is little information on the causes of myeloproliferative disorders (MPDs). In 2010 we conducted a review of all published studies which have investigated…
The day was packed with talks covering the individual MPD conditions, treatments and the latest medical options as well as fascinating updates on the…
Researchers have reported the results of the first JAK inhibitor study in Europe, and there is good news: the results were very positive.
Fifteen years after learning he had polycythaemia vera (PV), a patient has found in the last few years that his red cell counts have increased, requiring…
Five years ago we made several discoveries crucial to our understanding of myeloproliferative diseases.
Is it better to test positive or negative for the JAK2 mutation? It’s a question we often hear from people with MPDs.
Several new drug studies will open in the UK over the next few months to test promising treatments for myeloproliferative disorders (MPDs).
Many people with MPDs test positive for a mutation in a molecule called JAK2. Researchers believe that inhibiting JAK2 will be the most promising path…
The discovery of the JAK2 V617F mutation in 2005 has triggered an explosion in research into myeloproliferative disorders (MPD).
The discovery of the JAK2 V617F mutation in 2005 has triggered an explosion in research into myeloproliferative disorders (MPD).